| First Author | Laranjeira ABA | Year | 2024 |
| Journal | Blood | Volume | 143 |
| Issue | 23 | Pages | 2414-2424 |
| PubMed ID | 38457657 | Mgi Jnum | J:350973 |
| Mgi Id | MGI:7664647 | Doi | 10.1182/blood.2023022804 |
| Citation | Laranjeira ABA, et al. (2024) In vivo ablation of NF-kappaB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood 143(23):2414-2424 |
| abstractText | Hyperactivation of the NF-kappaB cascade propagates oncogenic signaling and proinflammation, which together augments disease burden in myeloproliferative neoplasms (MPNs). Here, we systematically ablate NF-kappaB signaling effectors to identify core dependencies using a series of primary samples and syngeneic and patient-derived xenograft (PDX) mouse models. Conditional knockout of Rela attenuated Jak2V617F- and MPLW515L-driven onset of polycythemia vera and myelofibrosis disease hallmarks, respectively. In PDXs, RELA knockout diminished leukemic engraftment and bone marrow fibrosis while extending survival. Knockout of upstream effector Myd88 also alleviated disease burden; conversely, perturbation of negative regulator miR-146a microRNA induced earlier lethality and exacerbated disease. Perturbation of NF-kappaB effectors further skewed the abundance and distribution of hematopoietic multipotent progenitors. Finally, pharmacological targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) with inhibitor CA-4948 suppressed disease burden and inflammatory cytokines specifically in MPN without inducing toxicity in nondiseased models. These findings highlight vulnerabilities in MPN that are exploitable with emerging therapeutic approaches. |
